女性癌症的治疗进展
Therapeutic advances in women's cancers.
作者信息
Carroll Amy R, Coleman Robert L, Sood Anil K
机构信息
Department of Gynecologic Oncology, M.D. Anderson Cancer Center, Houston, TX 77030, USA.
出版信息
Front Biosci (Schol Ed). 2011 Jan 1;3(1):82-97. doi: 10.2741/s134.
Abstract
Cytotoxic therapy and surgery have improved outcomes for patients with gynecologic malignancies over the last twenty years, but women's cancers still account for over ten percent of cancer related deaths annually. Insights into the pathogenesis of cancer have led to the development of drugs that target molecular pathways essential to tumor survival including angiogenesis, DNA repair, and apoptosis. This review outlines several of the promising new biologically targeted drugs currently being tested to treat gynecologic malignancies.
摘要
在过去二十年中，细胞毒性疗法和手术改善了妇科恶性肿瘤患者的治疗效果，但女性癌症仍占每年癌症相关死亡人数的10%以上。对癌症发病机制的深入了解促使了针对肿瘤生存所必需的分子途径（包括血管生成、DNA修复和细胞凋亡）的药物的开发。本综述概述了目前正在测试用于治疗妇科恶性肿瘤的几种有前景的新型生物靶向药物。
相似文献
1
Therapeutic advances in women's cancers.女性癌症的治疗进展
Front Biosci (Schol Ed). 2011 Jan 1;3(1):82-97. doi: 10.2741/s134.
2
Angiogenesis as a therapeutic target in urothelial carcinoma.血管生成作为膀胱癌的治疗靶点。
Anticancer Drugs. 2010 Nov;21(10):890-6. doi: 10.1097/CAD.0b013e32833e83b2.
3
Antiangiogenic therapy for breast cancer.乳腺癌的抗血管生成治疗。
Breast Cancer Res. 2010;12(5):209. doi: 10.1186/bcr2642. Epub 2010 Sep 29.
4
The role of antiangiogenesis therapy: bevacizumab and beyond.抗血管生成疗法的作用：贝伐单抗及其他。
Clin Transl Oncol. 2009 Jun;11(6):349-55. doi: 10.1007/s12094-009-0368-0.
5
Emerging therapies targeting tumor vasculature in multiple myeloma and other hematologic and solid malignancies.针对多发性骨髓瘤和其他血液系统及实体恶性肿瘤的肿瘤血管生成的新兴治疗方法。
Curr Cancer Drug Targets. 2011 Nov;11(9):1005-24. doi: 10.2174/156800911798073113.
6
Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes.贝伐单抗、舒尼替尼和索拉非尼单药或联合使用对血管内皮生长因子（VEGF）抑制人单核细胞分化为树突状细胞作用的影响。
Br J Cancer. 2009 Apr 7;100(7):1111-9. doi: 10.1038/sj.bjc.6604965. Epub 2009 Mar 10.
7
[Novelties in the treatment for advanced renal-cell cancer].[晚期肾细胞癌治疗的新进展]
Orv Hetil. 2011 Apr 24;152(17):655-62. doi: 10.1556/OH.2011.29100.
8
Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.肾细胞癌中血管内皮生长因子靶向治疗：现状与未来方向
Clin Cancer Res. 2007 Feb 15;13(4):1098-106. doi: 10.1158/1078-0432.CCR-06-1989.
9
VEGF inhibition and metastasis: possible implications for antiangiogenic therapy.血管内皮生长因子抑制与转移：抗血管生成治疗的潜在影响
Cancer Biol Ther. 2009 Jul;8(13):1214-25. doi: 10.4161/cbt.8.13.8918. Epub 2009 Jul 4.
10
[New possibilities of targeted therapy in the treatment of hepatocellular carcinoma with the help of molecular biology].[借助分子生物学进行肝细胞癌靶向治疗的新可能性]
Orv Hetil. 2010 Oct 24;151(43):1763-8. doi: 10.1556/OH.2010.28984.
引用本文的文献
1
Targeted drug delivery via folate receptors in recurrent ovarian cancer: a review.叶酸受体靶向药物递送在复发性卵巢癌中的应用：综述。
Onco Targets Ther. 2014 Jul 10;7:1223-36. doi: 10.2147/OTT.S40947. eCollection 2014.
本文引用的文献
1
Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study.贝伐珠单抗治疗复发性或持续性子宫内膜癌的 II 期临床试验：一项妇科肿瘤学组研究。
J Clin Oncol. 2011 Jun 1;29(16):2259-65. doi: 10.1200/JCO.2010.32.6397. Epub 2011 May 2.
2
Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer.卡铂、紫杉醇联合 Combretastatin A4 磷酸盐治疗铂类耐药卵巢癌的 II 期临床试验
Ann Oncol. 2011 Sep;22(9):2036-2041. doi: 10.1093/annonc/mdq708. Epub 2011 Jan 27.
3
A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study.一项舒尼替尼治疗复发性上皮性卵巢癌和原发性腹膜癌患者的 II 期研究：加拿大国立癌症研究所临床试验组研究。
Ann Oncol. 2011 Feb;22(2):335-40. doi: 10.1093/annonc/mdq357. Epub 2010 Aug 12.
4
Phase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.帕唑帕尼或拉帕替尼单药治疗与帕唑帕尼联合拉帕替尼联合治疗在晚期和复发性宫颈癌患者中的 II 期、开放标签研究。
J Clin Oncol. 2010 Aug 1;28(22):3562-9. doi: 10.1200/JCO.2009.26.9571. Epub 2010 Jul 6.
5
The role of HER2 in cancer therapy and targeted drug delivery.HER2 在癌症治疗和靶向药物递送中的作用。
J Control Release. 2010 Sep 15;146(3):264-75. doi: 10.1016/j.jconrel.2010.04.009. Epub 2010 Apr 10.
6
Notch signaling: emerging molecular targets for cancer therapy.Notch 信号通路：癌症治疗的新兴分子靶点。
Biochem Pharmacol. 2010 Sep 1;80(5):690-701. doi: 10.1016/j.bcp.2010.03.026. Epub 2010 Mar 31.
7
Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes.核 Notch3 在宫颈鳞状细胞癌中的表达及其与不良临床结局的关系。
Gynecol Oncol. 2010 Jun;117(3):409-16. doi: 10.1016/j.ygyno.2010.03.004. Epub 2010 Mar 31.
8
The role of microRNAs in ovarian cancer initiation and progression.微小 RNA 在卵巢癌发生和进展中的作用。
J Cell Mol Med. 2010 Sep;14(9):2240-9. doi: 10.1111/j.1582-4934.2010.01058.x.
9
Dasatinib: a potent SRC inhibitor in clinical development for the treatment of solid tumors.达沙替尼：一种在研的 SRC 抑制剂，用于治疗实体瘤。
Cancer Treat Rev. 2010 Oct;36(6):492-500. doi: 10.1016/j.ctrv.2010.02.015. Epub 2010 Mar 11.
10
Disrupting established tumor blood vessels: an emerging therapeutic strategy for cancer.破坏已建立的肿瘤血管：癌症治疗的新策略。
Cancer. 2010 Apr 15;116(8):1859-71. doi: 10.1002/cncr.24975.
Zotero 插件